Caris Launches ‘Behind the Diagnosis’ Campaign Highlighting 3.1% Misdiagnosis Rate
CAI•Caris Life Sciences launched its Behind the Diagnosis campaign, highlighting Caris GPSai’s AI-based tissue-of-origin model correcting a patient’s stage 4 triple-negative breast cancer to treatable Hodgkin lymphoma. FDA-approved Caris GPSai in MI Cancer Seek flagged misdiagnosis in 3.1% of cases, altering therapy for 71.5% of patients in a 3,958-case study.
1. Campaign Launch and Patient Impact
Caris Life Sciences launched the Behind the Diagnosis campaign with an inaugural story featuring Erika Rios, whose initial stage 4 triple-negative breast cancer diagnosis was corrected by Caris GPSai to Hodgkin lymphoma, enabling a treatable therapy pathway and emotional relief.
2. AI Technology and FDA Approval
Caris GPSai is an AI-powered tissue-of-origin model integrated into Caris MI Cancer Seek, the first and only simultaneous Whole Exome Sequencing and Whole Transcriptome Sequencing–based assay approved by FDA as a companion diagnostic for solid tumors and offered at no additional cost.
3. Study Findings and Clinical Implications
A peer-reviewed analysis of 3,958 presumed lung squamous cell carcinoma cases identified a 3.1% misdiagnosis rate, with Caris GPSai redirecting 71.5% of those patients to guideline-preferred first-line systemic therapies, demonstrating significant clinical impact from early AI-augmented profiling.
